Filing Details
- Accession Number:
- 0001562180-18-001642
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-03-16 10:09:08
- Reporting Period:
- 2018-03-15
- Accepted Time:
- 2018-03-16 10:09:08
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1560241 | G1 Therapeutics Inc. | GTHX | Pharmaceutical Preparations (2834) | 263648180 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1706853 | Rajesh Malik | C/O G1 Therapeutics, 79 Tw Alexander Dr. 4501 Research Commons, Suite 100 Research Triangle Park NC 27709 | Ch. Medical Officer & Svp R&D | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-03-15 | 496 | $4.17 | 4,696 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2018-03-15 | 3,280 | $0.39 | 7,976 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-03-15 | 3,776 | $38.18 | 4,200 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Options (Right to Buy) | Disposition | 2018-03-15 | 496 | $0.00 | 496 | $4.17 |
Common Stock | Stock Options (Right to Buy) | Disposition | 2018-03-15 | 3,280 | $0.00 | 3,280 | $0.39 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
99,503 | 2026-05-10 | No | 4 | M | Direct | |
0 | 2023-12-05 | No | 4 | M | Direct |
Footnotes
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
- The price represents the weighted average price with a low of $38.01 and a high of $38.42.
- The shares underlying this option vested as to 25% of the shares on May 10, 2017, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
- All shares underlying this option have vested.